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 Abstract 
Theoretical reasoning suggests that human cancer may result from knocking 
down the genetic constraints evolved for maintenance of the metazoan 
multicellularity, which, however, requires a critical test.  Using xenograft-based 
experimental evolution we characterized for the first time the full life history from 
initiation to metastasis of a tumor at the genomic and transcriptomic levels, and 
observed metastasis-driving positive selection for generally loss-of-function 
mutations on a set of multicellularity-related genes, which is further supported by 
large-scale exome data of clinical tumor samples.  Subsequent expression analysis 
revealed mainly expression down-regulation of multicellularity-related genes, which 
form an evolving expression profile approaching that of embryonic stem cells, the 
cell type with the most characteristics of unicellular life.  The theoretical conjecture 
predicts that genes born at the emergence of metazoan multicellularity tend to be 
cancer drivers, which we validated using a rigorous phylostratigraphy analysis on the 
birth rate of genes annotated by Cancer Gene Census.  Also, the number of 
loss-of-function tumor suppressors often predominates over activated oncogenes in a 
typical tumor of human patients.  These data collectively suggest that, different 
from typical organismal evolution in which gain of new genes/functions is the 
mainstream, cancer represents a loss-of-function-driven degenerative evolution back 
to the unicellular “ground state”.  This cancer evolution model may explain the 
enormous inter-/intra-tumoral genetic heterogeneity in the clinic, underlie how 
distant-organ metastases originate in primary tumors despite distinct environmental 
requirements, and hold implications for designing effective cancer therapy. 
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 Introduction 
Unicellular life appeared earlier on the earth; group selection for the public good 
promoted cooperation of the single-celled individuals, eventually leading to 
multicellular life 1.  Complex multicellular organisms, including humans, must 
possess sophisticated genetic constraints that suppress the fitness of individual cells 
in order to ensure the fitness of the whole organism 2.  However, accidental events 
such as somatic mutations or viral infections can wipe out such constraints and 
reactivate the cell’s otherwise dormant capacity of seeking for its own fitness, often 
resulting in cancer 3-5.  In this regard, cancer represents a reversal of the 
macroevolution from unicellular life to multicellular life6-8.  This reasonable 
conjecture has important implications for cancer research, cancer prevention and 
cancer therapy, but has never been tested rigorously. 
We carried out an experimental evolution9,10 of a human breast cell-derived 
xenograft tumor in mice to characterize the complete evolutionary history of a tumor, 
attempting to address the question.  Although the micro-environment of mouse 
mammary gland is not ideal for studying human breast cancer, such a strategy has 
long been used to study the genetics underlying tumorigenesis, tumor progression 
and metastasis11, and has been proven highly successful in human cancer biology12.  
Similar to a pioneer study13, we engineered a mutated version of human oncogene 
HRASV12 into the otherwise normal immortalized human breast epithelial cell line 
MCF10A, to obtain an early transformed cell population MCF10A-HRAS.  
MCF10A-HRAS was subsequently xenografted into NOD/SCID mice to develop the 
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 first-stage xenograft tumor (XT1).  The cell population of the XT1 was xenografted 
again to develop the second-stage xenograft tumor (XT2).  This procedure was 
repeated until two metastatic tumors were observed in the mouse carrying XT8 (Fig. 
S1).  Cell samples from MCF10A-HRAS, XT1, XT2, XT3, XT4, XT5, XT6, XT7, 
XT8, and the two metastatic tumors XT8_M1 and XT8_M2 are in clear temporal 
order, together representing the cancer’s full life history from initiation to metastasis.  
We then performed comparative genomic hybridization (Table S1), high-depth 
(~250X) exome sequencing (Table S2), and RNA sequencing (Table S3 and Fig. S2) 
for each of the cell samples, and built the first high time-resolution evolutionary 
roadmap of a tumor at the genomic and transcriptomic levels, revealing novel 
insights into cancer biology. 
 
Results 
The tempo-spatial distribution of intratumoral genetic heterogeneity 
Our experimental setting enabled a tempo-spatial dissection of intratumoral 
genetic heterogeneity 14,15.  There are 473 single-base substitution mutations that 
originated after XT1 and each shows varied allele frequencies at different tumor 
stages (Table S2).  We grouped mutations whose frequencies vary in a similar 
fashion, and identified five major mutation groups that together represent diverse 
subclones, which we validated by single cell analysis (Table S2).  There is a 
subclone that constitutes a minor fraction of cells while harboring the vast majority 
of detected mutations after XT4 (Fig. 1a), suggesting it is a mutator.  In this 
  4
 subclone we observed missense mutations on MLL3 and RAD54B, two genes 
required for maintaining genome stability, in XT4 and subsequent stages, and a 
missense mutation on PMS1, a gene involved in DNA mismatch repair, starting in 
XT7 (Fig. 1b), consistent with the identification of this sbuclone as a mutator and 
explaining the pattern of increased mutations in this subclone (Fig. 1a).  
Interestingly, the two metastases XT8_M1 and XT8_M2 are seeded by the mutator 
subclone (Fig. 1a and Fig. S3), an observation reminiscent of a long-standing 
hypothesis that mutator phenotypes promote cancer evolution 16.   
 
The metastasis-driving positive selection on a set of multicellularity-related 
genes 
To understand what properties enabled the mutator subclone to seed the 
metastases, we studied the 137 genes that are mutated in the mutator subclone (from 
XT4 to XT8) using Gene Ontology (GO) analysis, and found that they are enriched 
exclusively in four closely related GO terms under a false discovery rate of 0.001 
(Fig. 1c), while we observed no significant GO enrichment for genes mutated in 
other subclones.  Among the four GO terms, “systems development” and “organ 
development” are children of the two highly similar sibling terms “multicellular 
organismal development” and “anatomical structure development”, which share 
~90% of genes with each other.   Because anatomical structure is apparently a 
feature specific to multicelluar organisms, all these GO terms were then considered 
to be multicellularity-related.  We examined the 15 mutated genes shared between 
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 the two sibling terms “multicellular organismal development” and “anatomical 
structure development”, and found 14 non-synonymous (missense and nonsense) 
mutations and 1 synonymous mutation on them, while we observed 81 
non-synonymous mutations and 43 synonymous mutations on the other 122 genes 
mutated in the mutator subclone, suggesting that the 15 multicelluarity-related genes 
tend to show functional changes (P < 0.04, two-tailed Fisher exact test).  We 
ignored the single gene carrying no non-silent mutation, leaving 14 genes as a set for 
further examination (Table S4).  None of the 14 genes belongs to the ~500 cancer 
drivers annotated by Cancer Gene Census (CGC) 17, and, in line with this, they are 
mutated only at the background frequency in breast cancer clinical samples (Fig. 1d).  
Interestingly, however, from a total of ~800 sequenced exomes of breast cancer 
clinical samples we observed 220 non-synonymous mutations and 37 synonymous 
mutations on the 14 genes, corresponding to an overall dN/dS = 2.13 (P < 10-5, 
Binomial test; Fig. 1e and Table S4), where dN stands for the number of 
non-synonymous mutations per non-synonymous site, and dS stands for the number 
of synonymous mutations per synonymous site.  This result is not due to a single 
outlier gene, because the dN/dS ratio remains largely unchanged (varied from 1.85 to 
2.22) after removing any one of the 14 genes, suggesting that the 14 
multicellularity-related genes are overall under positive selection in breast cancer.   
We noted that their tendency towards function-altering mutations appears to be 
stronger in our xenograft model (14:0) than in the clinical samples (220:37), 
although the difference is not statistically significant (P = 0.23, two-tailed Fisher 
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 exact test) due to limited sample sizes.  We speculate that the functional alterations 
of the 14 genes may directly contribute to metastasis, so that the signal from the 
metastases-seeding subclone in our xenograft model is stronger than the signal from 
the clinical samples that are mostly whole primary tumors containing 
non-metastasizing cancer cells which dilute the signal.  We examined ~100 
genome-wide screenings for mutations in metastatic tumors, and discovered 82 
non-synonymous mutations and 6 synonymous mutations on the 14 genes (Table S4).  
Thus, the tendency of having function-altering mutations is indeed stronger in 
metastatic tumors (P = 0.04, one-tailed Fisher exact test), a result well in line with 
our hypothesis that the positive selection on the 14 genes drives metastasis.  
Notably, in addition to 16 nonsense mutations, the 300 missense mutations examined 
here are distributed along the entire length of each of the 14 genes, without apparent 
hotspots (Fig. S4), suggesting that in general loss of function is positively selected 
for 18, although rare gain-of-function mutations may exist. 
 
An evolving expression profile from multicellularity to unicellularity 
We identified 12911 genes that show marked expression changes during tumor 
evolution.  Analogous to the concept of driver mutations and passenger mutations, 
these changes should include both driver expression changes (DEC) and passenger 
expression changes (PEC).  We reasoned that, compared to DEC that are beneficial 
to tumor cells, PEC subject to further expression reprogramming are less likely to 
have fitness costs, so the PEC genes tend to show both increasing and decreasing 
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 expression during the tumor life history.  With this logic in mind, we developed an 
algorithm and detected signature of PEC for the vast majority (~95%) of genes with 
marked expression changes.  The remaining ~700 genes show largely one-way 
change (i.e., either exclusively increasing or exclusively decreasing), and thus are 
likely to have undergone DEC (Table S3).  Consistently, gene set enrichment 
analysis (GSEA)19 showed that the ~700 genes with putative DEC are involved in a 
large number of known cancer-related pathways/processes (Table S5).  We found 
that up to 75.1% of these genes show reduced expressions, while the number is 
38.6% for the genes with signature of PEC (P < 10-16, Chi-square test; Fig. 2a), 
suggesting a “less is more” pattern in driver expression divergences.  A particularly 
interesting observation is that, similar to the genes that are mutated in the mutator 
subclone (Fig. 1c), the putative DEC genes are also overrepresented in a series of 
multicellularity-related GO terms (Fig. 2b).   Although inactivation of a specific 
gene can either strengthen or weaken a cellular process, the widespread shutting 
down of the genes necessary for development and maintenance of multicellularity 
suggests a general loss-of-function strategy to erase the cellular features of 
multicellularity during cancer.  
Some of the ~700 putative DEC genes are ubiquitously expressed in diverse 
normal tissues and some preferentially in breast.  It is interesting to know where the 
putative DEC genes preferentially expressed in breast evolves.  Following a 
previous study 20, we calculated a breast biased index (BBI) for each of the ~700 
putative DEC genes by dividing its expression level in breast by its median 
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 expression level in all sixteen normal tissues, and obtained 73 genes with BBI > 2 
(Table S6).  We clustered the expression profiles of the 73 genes in different tissues 
or cells.  MCF10A-HRAS, the starting cell population, is clustered with the normal 
breast tissue; interestingly, the ending cell population XT8 is clustered with 
embryonic stem (ES) cells (Fig. 2c).  In addition to their totipotency, an often 
underappreciated characteristic of ES cells is their rapid and excessive proliferation 
to form cell colony, a feature typical to unicellular life.  It seems more reasonable 
that the unicellularity, rather than the totipotency, of ES cells is mimicked by the XT 
cell populations during evolution.  There are 50 and 33 putative DEC genes with 
BBI larger than 3 and 5, respectively, with both sets showing the same pattern.   
 
The birth rate of cancer drivers is peaked on the deepest metazoan branch  
It is interesting to know how the findings from the experimental evolution of a 
breast tumor apply to clinical data of various cancers.  We reasoned that, to form 
the genetic network required for development and maintenance of multicellularity in 
humans after the origin of metazoan multicellularity, some pre-existing genes are 
co-opted and some new genes are gradually acquired during the course of evolution.  
It is conceivable that genes originating at the emergence of metazoan multicellularity 
should have a higher chance to contribute to the core multicellularity-related genetic 
network.  If cancer is indeed driven by demolishing the multicellularity-related 
genetic network, one would expect that there will be a surge in the probability of 
being cancer drivers for genes born at the emergence of metazoan multicellularity.  
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 This prediction is favored by a previous phylostratigraphy analysis which shows an 
elevated birth rate of cancer-related human genes on the branch connecting Holozoa 
and Metazoa 21.  The result, however, is confounded by the then-confusing 
phylogeny of deep animal clades, as well as evolutionary innovations other than the 
emergence of multicellularity during the up to hundreds million years of evolution.  
A more critical issue is the methodological bias of conventional phylostratigraphy 
analysis which defines gene origin based on simple BLAST22 hitting of the most 
distant clade/species, favoring conserved genes in deep branches.  Because cancer 
drivers are more conserved than the rest human genes (Fig. S5), a more rigorous 
dating of the origin of these genes is necessary for addressing this question.   
We assembled 37 completely sequenced genomes representing 13 major clades 
(Fig. 3a and Table S7), conducted all-against-all protein BLAST for 37*36/2 = 666 
species pairs, and built an orthology network in OrthoMCL23 that solves gene 
orthologous relationship using graph theory.  Compared to conventional 
phylostratigraphy that relies on a single round of BLAST, this approach may greatly 
reduce the aforementioned bias.  We successfully dated the origin of ~21,000 
human genes, including 488 cancer drivers annotated by CGC.  As a control, we 
carried out a simulation by randomly picking 488 genes with evolutionary rates 
comparable to the 488 cancer drivers, to derive the null distribution.  We ran the 
simulation 13,000 times, and found that genes originating on the Branch #3 (or B3) 
are the only group comprising significantly more cancer drives than expected (P < 
0.01 after Bonferroni correction; Fig. 3b).  It is known that emergence of early 
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 metazoan clades are compressed in time 24, with an unresolved phylogenetic 
relationship until very recently 25.  The Branch #2 (or B2) connects unicellular life 
with the oldest multicellular lineage Ctenophora, so the short B3 is the deepest 
branch specific for metazoans (Fig. 3a).  Thus, the observation of a significantly 
higher proportion of cancer drivers on the deepest metazoan branch is consistent 
with the argument that cancer is a process of demolishing the genetic network 
evolved for development and maintenance of multicellularity.   
 
The loss-of-function-dominant evolution in tumors of human patients 
There are two groups of cancer drivers, oncogenes and tumor suppressors.  The 
former drives cancer mostly by gain of function, while the latter by loss of function.  
There are currently a comparable number of oncogenes and tumor suppressors 
characterized at CGC.  Interestingly, investigation of thousands of clinical samples 
showed that the number of inactivated tumor suppressors often predominates over 
that of activated oncogenes when a single tumor is considered (the former is ~2.3 
times the latter in a typical solid tumor) 18.  This number should still be an 
underestimation, because a large number of genes normally for maintenance of 
multicellularity are expected to be unrecognized minor tumor suppressors.  
Motivated by this prediction, we developed a new statistical test, namely the dT/dS 
ratio test, to compute the relative truncating substitution mutation rate (dT) to 
synonymous substitution mutation rate (dS) in cancer; observation of dT/dS ratio 
significantly larger than one indicates positive selection for null mutations, which is 
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 a unique signature of tumor suppressor genes.  The design of the dT/dS test 
circumvents the problem of low specificity caused by among-gene mutation 
heterogeneity, a major flaw of conventional methods 26, while maintaining high 
sensitivity in identifying minor tumor suppressors (Fig. S6).  Using this new 
method, we analyzed data from The Cancer Genomic Atlas (TCGA) and 
successfully identified as many as 134 novel putative tumor suppressors under a 
false discovery rate of 0.1 (Table S8), a finding reminiscent of a recent study 27 and 
challenging the view that the growth of cancer gene list has reached a plateau 18.  It 
is conceivable that most of the newly identified tumor suppressors are minor cancer 
drivers, conferring small fitness advantages in primary tumors.  Because of clonal 
interference28 in which large-effect beneficial mutations suppress small-effect 
beneficial mutations in an asexual population, minor cancer genes may become 
effective mostly at late stages of cancer evolution when the pool of large-effect 
beneficial mutations becomes shallow, suggesting their roles on promoting 
malignancy or metastasis.  Of particular interest is the fact that the 134 novel tumor 
suppressors are enriched exclusively in the same four multicellularity-associated GO 
terms as shown in the Fig. 1c (Fig. S7). 
 
Discussion 
 A caveat of this study is that only a single tumor life history was examined, so 
some of the patterns can be rules and some are just exceptions.  Importantly, the 
two major findings from the experimental evolution are well supported by data from 
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 clinical samples or from other studies, suggesting the generality of our results: 1) the 
metastasis-driving positive selection on the small set of multicellularity-related 
genes was first suggested by mutations in the experimental evolution, and then 
systematically demonstrated by data from hundreds of clinical samples; 2) the 
putative DEC genes were identified based on their one-way expression changes 
during the experimental evolution, and may contain false positives.  But, this 
should have diluted the signal that they are overrepresented in known cancer gene 
sets.  In addition, by using an isogenically matched cell model with three 
oncogenes added in an accumulative order to mimic the expression divergences 
during cancer, people found that ~80% of the differentially expressed genes are 
down-regulated 29; analysis of these genes revealed that they are highly enriched in 
multicellularity-related GO terms (Fig. S8), paralleling the findings of our 
experimental evolution.   
 
 The idea of cancer as an evolutionary process was first coined by Nowell ~40 
years ago 30.  The landmark paper distinguished cancer from genetically inheritance 
diseases that often have a static mutated genome, providing a basic theoretical 
framework to guide cancer research and cancer therapy in the past decades.  
Typically, gain of new genes/function seems to be the mainstream of organismal 
evolution 31,32, despite many reports of “less is more” 33,34.  However, cancer cells 
resemble unicellular life in most of their hallmarks 35, such as sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling 
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 replicative immortality, and fermentative metabolism.  Although tumors are not 
unicellular entities as far as the physical structure is concerned, tumor cells are 
evolving towards the biological status in which individual cells proliferate for their 
private fitness, the essence of being unicellular life.  Given that the whole set of 
cellular machinery necessary to unicellular life is already available in a human cell, 
cancer may reactivate the otherwise dormant pre-existing functions by knocking 
down the genetic constraints required for maintenance of multicellularity.  Such a 
concept is not new, and actually quite obvious to evolutionists from a theoretical 
point of view 6-8, but rigorous test and systematic demonstration based on 
experimental/clinical data lack.  In this article, we assembled various lines of 
empirical evidence into a reasonably convincing package for supporting the 
theoretical conjecture that cancer cells evolve back to be unicellular, a process 
reminiscent of degenerative evolution (or devolution).  Equally importantly, we 
suggested that principles behind the cancer devolution can be very different from 
principles underlying typical gain-of-function-dominated organismal evolution 31: 
First, although gain of new function is sometimes necessary, for example, for 
initiating transformation 36, cancer devolution can be driven by the beneficial loss of 
function 37,38 of the existing genes that are numerous in the human genome.  
Considering that loss-of-function mutations are often much more accessible than 
gain-of-function mutations 33, devolution via loss of function seems to be a highly 
efficient strategy for cancer given its short-term time frame 39.  Indeed, the 
experimental data of this study showed that loss-of-function genetic or expression 
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 alterations are predominant, and it is also true in clinical samples 18.  Thus, the 
model of devolution via mainly loss of function challenges the view suggested by 
typical organismal evolution 31 that cancer progresses to build a new genetic network; 
instead, it progresses to demolish the existing multicellularity-related genetic 
network to reactivate the “genetic memory” of being unicellular7.  This has 
important implications for thinking of the evolutionary contingency and convergence 
in cancer, explaining well the enormous inter-/intra-tumoral genetic heterogeneity in 
the clinic 40-42, because the means of knocking down a system can be numerous. 
Second, the conventional evolutionary theories are also difficult to explain the 
origin of distant-organ metastasis within a primary tumor, because the metastatic site 
is often very different from the primary site in cell-biological requirements 43.  We 
reason that, to establish a distant-organ metastasis, cells of a primary tumor need to 
shut down genes that respond to signals specifying the cells’ tissue identity, which is 
exactly the direction of devolution back to be unicellular.  It is conceivable that a 
fully “unicellularized” cancer cell behaving like a bacterium is presumably able to 
colonize anywhere of the human body.  Thus, distant-organ metastasis represents 
the very late stage of devolution which is, irrespective of external environments, 
internally driven by the loss of multicellularity-associated constraints.  Primary 
tumor formation and metastatic colonization are therefore unified by the same 
devolutionary process.  It is worth pointing out that there seems to be no major 
genes (like TP53 for primary tumors) that are frequently mutated to promote 
metastatic colonization in clinical samples 44, suggesting that the capacity of 
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 metastasizing is a complex trait governed by a large number of mutations/genes that 
are either large-effect with low frequency or small-effect with high frequency, and 
thus calling for a quantitative genetic approach to map metastasis drivers 45. 
It should be emphasized that we here argue for devolution during cancer as far 
as the basic features of multi-/uni-cellularity are concerned.  It is apparently 
impossible that cancer cells degenerate to become the primitive ancestor living over 
600 million years ago.  While the model of devolution via loss of function offers a 
general theoretical framework for understanding cancer, we are fully aware that 
devolution is certainly not the full story of such a complex disease, and many cancer 
related processes, such as angiogenesis, immune evasion, tissue infiltration, and so 
on, may rely on evolutionary innovations rather than simple degeneration.  
Separation of such innovative processes from degenerative processes would be 
critical for designing effective cancer therapy, because attempts to stop an ongoing 
degeneration towards the unicellular “ground state” seem unlikely to succeed. 
 
Materials and Methods 
All experiments involving animals were done in the Animal Center of SYSU, in 
accordance to the guidelines of the center. 
The 10-stage cell populations.  A DNA fragment containing HRASV12 46, an 
internal ribosome entry site (IRES), and the coding sequence of green fluorescent 
protein (GFP) was inserted into the vector pBABE-puro47 to form 
pBABE-puro-HRASV12, the sequence of which was then verified by Sanger 
sequencing.  This construct was introduced into the immortalized human breast cell 
line MCF10A that is purchased from ATCC, using a retrovirus following standard 
protocol.  GFP positive cells were selected by flow cytometry, resulting in the 
MCF10A-HRAS cell population.  About 5x106 MCF10A-HRAS cells were injected 
into the abdominal mammary fat pad of each of three six-week-old female 
NOD/SCID mice.  One mouse developed a xenograft tumor about two months later, 
which was harvested after two months at a diameter of ~2cm and designated as XT1.  
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 The tumor was dissected into small pieces, and suspended in pre-warmed digesting 
solution, prepared by adding 0.1mg/ml DNase I (Sigma DN25), 0.1mg/ml HAse 
(Sigma H6254), 5mg/ml Collagenase IV (Sigma C5138), 10% FBS (Gibco C20270) 
to DMEM-F12 (Gibco 11330-032).  After a two hour digestion at 37 ºC the product 
was washed with PBS and then cultured in DMEM-F12 with 50% FBS at 37 ºC, in 
an incubator with 5% CO2.  About 107 to 108 adherent cells were harvested 2 days 
later.  We used biotin-labeled Anti-Mouse H-2K[d] antibody (BD 553564) to label 
contaminating mouse cells, and subsequently depleted these with Dynabeads Biotin 
Binder (Life Technology 11047).  The resulting XT1 cell population was used for 
further xenografting, DNA and RNA extraction, and liquid nitrogen stock 
preparation.  The other XT cell populations were obtained through a similar 
procedure. 
The immortalized MCF10A and MCF10A-HRAS cells were cultured in 
DMEM-F12 containing 5% Horse Serum (Gibco 16050-122), and with supplements 
of 20ng/ml EGF (Gibco PHG0311), 0.5mg/ml Hydrocortisone (Sigma H0888), 
100ng/ml Cholera Toxin (Sigma C8052), and 10ug/ml Insulin (Sigma I1882).  
Because most of the above supplements are no longer required for transformed XT 
cells, all XT cells are cultured in DMEM-F12 containing 10% FBS, with none of the 
above supplements.  The change has minimal effect on gene expressions, as 
evidenced by the highly similar expression profiles of XT1 cell populations growing 
in the two media (R = 0.98; Table S9). 
 
Comparative genomic hybridization (CGH).  Genomic DNA of ~5x106 cells was 
extracted using DNeasy Kit (Qiagen 69504) and digested by NspI (NEB R0602L) or 
StyI (NEB R0500L).  Adaptors were ligated to the DNA fragments for PCR 
amplification.  Amplified DNA was labeled with biotin using Affymetrix 
Genome-Wide Human SNP Nsp/Sty Assay Kit 6.0 (Affymetrix 901015).  
Hybridization was performed according to Affymetrix Genome-Wide Human SNP 
Nsp/Sty 6.0 User Guide (Affymetrix 702504).  Arrays were then scanned by 
GeneChip Scanner 3000 (Affymetrix).  Genotype and copy number of each probe 
or genomic segment were calculated by Genotyping Console Software 4.1 
(Affymetrix).  Table S1 contains the data. 
 
Exome sequencing.  Genomic DNA of ~5x106 cells was extracted using DNeasy 
Kit (Qiagen 69504), and was sheared by Covaris.  Fragments between 200bp and 
300bp were collected for library construction following TruSeq DNA Guide 
(Illumina).  The genomic DNA library was hybridized to Human Exome 2.1M 
Array (Nimblegene 05-547-792-001) for exome enrichment, and then subject to 
Illumina GAII or HiSseq sequencing.  About 120 million 90bp reads were 
generated for each sample, corresponding to an average sequencing depth of ~250x 
for the exome.  The reads were mapped to hg19 (UCSC) by bowtie2 with default 
settings, and duplicated reads were removed by Picard.  Single nucleotide variants 
(SNVs) and indels were called on GATK platform with default settings, and only 
those that can pass all GATK filters were used.  The resulting data are highly 
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 reliable, as evidenced by the fact that the vast majority of variants called at a given 
stage were also found at the later stage.  All SNVs and indels genotyped as 0/1 or 
1/1 in MCF10A or MCF10A-HRAS were considered as germ-line SNPs or indels, 
and were excluded from further analysis.  Table S2 contains the data. 
 
Poly(A)+ RNA sequencing.  Total RNA of ~3x106 cells was extracted using 
RNeasy Kit (Qiagen 74134,79654), followed by DNase I (Promega RQ1 RNase Free 
DNase) treatment to eliminate DNA contamination.  Samples with RNA integrity 
number (RIN) greater than 9.5 (Agilent 2100 Bioanaylzer) were used.  Poly(A)+ 
mRNA was isolated with Dynabeads Oligo(dT)25 (Life technology 61005).  
Libraries were constructed following TruSeq RNA Guide (Illumina), and subject to 
Illumina GAII or HiSseq sequencing.  About 20 million 75bp reads were generated 
for each sample.  The RNA-seq reads were mapped to hg19 (UCSC) by bowtie2 
with default settings. Reads with mapping quality higher than 20 and mapped to 
exon regions (Ensemble 69) were considered as unique hits.  For genes with 
alternative splicings, only exons from the longest transcript were considered.  The 
RPKM of a gene was calculated similarly to previous study 48.  The effective length 
of a gene was defined as the total number of the 75-mers in all its exons that hits no 
elsewhere of the genome. We excluded genes with effective length less than 100bp 
from subsequent analysis.  Table S3 contains the data. 
 
Separation of intratumoral subclones.  We started from the 8081 substitution 
mutations that were sequenced with >30x coverage in all samples.  We excluded 
7608 sites that were annotated as the same genotype by GATK in all XT samples to 
simplify the procedure of subclone separation.  The remaining 473 sites were 
hierarchically clustered according to their mutant allele frequencies, which often 
vary at different tumor stages.  We observed 72 sites that show mutations 
specifically in XT8_M1, and for the rest mutations we identified four major groups 
together representing diverse subclones.  There are 15 sites that cannot be reliably 
grouped.  The relationships of the mutation groups were resolved by reasoning and 
further experimental validation.  To define a mutation present at a specific stage, we 
required that the mutant allele frequency is >1%.   
We used serial dilution to obtain single cells that are seeded onto 96-well plates.  
Microscopic observation confirmed those wells that contain only one cell.  At a 
very low frequency (<1%), we obtained small colonies each consisting of at least a 
few tens of cells in a well.  Genomic DNA was extracted from such colonies and 
then used for assessment of intratumoral subclone separation.  Table S2 contains 
the data. 
 
Determination of allele information for four mutations shared between XT8 and 
the two metastases.  For each of the four mutations there is a neighboring 
germ-line single nucleotide polymorphism (SNP) that identifies the two alleles of the 
locus.  High-fidelity polymerase chain reactions (PCR) followed by TA cloning and 
Sanger sequencing were performed in XT8_M1 and XT8_M2, respectively, to trace 
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 the allele information of the mutations.  Figure S3 contains the data. 
 
Detection of positive selection.  All mutation data from clinical cancer samples 
were retrieved from TCGA 49 and COSMIC 50.  The mutation spectrum of breast 
cancer was determined by analyzing substitution mutations in breast cancer exomes 
sequenced by TCGA, with only four-fold degenerate sites of protein-coding genes 
being considered.  Using the breast cancer mutation spectrum, we then computed 
the number of non-synonymous (missense and nonsense) sites and synonymous sites 
of the merged coding sequences of the 14 multicellularity-related genes, in order to 
estimate their dN and dS in the breast cancer clinical samples.  We examined the 
locations and neighboring bases for all the non-synonymous and nonsense mutations 
of the 14 genes observed in the xenograft tumors and the clinical samples, and 
confirmed that the high dN/dS ratios cannot be explained by a few extremely biased 
mutation hotspots or certain biased mutation motifs.  Table S4 contains the data. 
 
Identification of putative driver expression changes (DEC).  We defined a gene 
with marked expression change using two criteria: 1) there is more than two-fold 
difference between the maximum and minimal expressions of the 12 samples, and 2) 
the difference is statistically significant at q < 0.001 (Bonferroni correction).  A 
total of 12911 genes show marked expression changes, with ~40% being largely 
down-regulated (correlation coefficient R < 0) during the tumor evolution.  To 
define one-way expression divergence (or putative DEC), two rounds of analyses 
were carried out, each with 11 cell samples (10 earlier samples and one of the two 
metastases) sorted according to their temporal order. For a gene with elevated (or 
reduced) one-way expression divergence three criteria should be met: 1) its 
maximum expression among the 11 samples appears later (or earlier) than its 
minimal expression; 2) for all pairwise comparisons, the earlier sample cannot be 
higher (or lower) than the latter sample by >10% of the difference between the 
maximum and minimal expressions; and (3) the above two criteria are met in both 
rounds of analyses where a different metastasis sample is examined. Among the 
12911 genes with marked expression changes, less than 6% (758) met these criteria.  
Fifty-five genes were completely silenced after HRAS transfection, and thus are not 
considered because only the stochastic evolutionary process was interested here; the 
remaining 703 genes are subject to further analyses.  Correlation analysis revealed 
that ~75% of these genes were down-regulated (indicating by the negative 
correlation coefficient between the ranking of evolution stages and the expression 
levels; R < 0) during tumor evolution.  Table S3 contains the data. 
 
Dating the origin of human genes.  We included 13 major clades from 
single-celled organisms to non-human primates, with consideration of previous 
reports 6,24,25,51-53 regarding the phylogeny, to trace the origin of 23,695 human 
protein-coding genes.  Orthologous relationship of the human genes and genes of 
organisms in the 13 major cladenfgx s was determined using OrthoMCL with default 
settings.  For a given human gene, we first determined the most distant clade 
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 containing the gene’s orthologos, and then assigned its birth to the latest common 
branch of human and that clade.  To avoid the potential age inflation due to 
horizontal gene transfer or unreliable orthology assignment, we required that the 
gene (or its orthologos) can be found in at least one additional clade, except for 
genes born at B12.  Cases not satisfying this criterion were excluded, remaining 
21352 human genes including 488 cancer drivers with birth time assigned.  The 
birth rate of cancer drivers on a given branch was defined as the number of cancer 
drivers born on the branch divided by the total number of human genes born on the 
branch. 
The completeness of selected genomes in the 13 clades is critical, which was 
evaluated using a previously described method 54.  Briefly, a set of genes basic to 
all eukaryotes are used to query the selected genomes, and observation of 100% 
presence is desired.  We selected 36 species with sequenced genomes to represent 
the 13 clades, with a minimal completeness of ~96% at the clade Placozoa.  
Inclusion of more genomes does not improve the performance.  The major point of 
this analysis lies in the three clades (Placozoa, Porifera, and Ctenophora) 
representing early multicellular animals.  To model the potential bias due to sparse 
sampling of the three clades, we performed 100 times simulations by randomly 
removing 10% of genes of the genomes in each of the three clades, and found that 
the overrepresentation of cancer genes at the Branch #3 remains qualitatively 
unchanged (Fig. S9).   
To control for protein evolutionary rate in the phylostratigraphy analysis, we 
sorted the 21352 genes according to their dN between human and chimpanzee (the 
results are essentially the same when dN between human and rhesus monkey were 
used.), and then divided them into 100 equal-size bins (the fastest evolving bin has 
213+52=265 genes).  We randomly pick n genes from a bin, where n is the number 
of cancer drivers in the bin, to form a pseudo-cancer driver set with 488 genes; the 
birth rate of the pseudo-cancer drivers on each of the 13 branches is then calculated.  
Such simulation was repeated 13,000 times, to make a test at the significance level 
of P = 0.01 after Bonferroni correction.  Table S7 contains species and gene 
information used in this analysis.  
 
Indentification of putative tumor suppressor genes using dT/dS ratio test.  We 
downloaded TCGA level 3 data of substitution mutations from TCGA data portal; in 
total, 776 BRCA, 269 COAD, 291 GBM, 306 HNSC, 422 KIRC, 520 LUAD, 178 
LUSC, 463 OV, 116 READ, 266 SKCM, 245 STAD, 406 THCA and 248 UCEC 
tumors were considered.  For each cancer type we analyzed the single-base 
substitution mutations at four-fold degenerate sites of protein-coding genes to derive 
mutation spectrum of that cancer.  In addition to the six regular types of substitution 
mutations, mutations of ApT->ApA, CpG->TpG, TpC->TpX (X: A, T, and G), and 
TpCpG->TpTpG (the combination of TpC and CpG) were separately considered 26.  
In other words, we computed the mutation rate U for each of the 12 mutation types 
in each cancer to estimate the expected truncating vs synonymous (T/S) site ratio of 
a gene.  For a hypothetical gene with 100 codons, we would consider 900 mutation 
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 possibilities; for each mutation possibility the expected rate is the U of the 
corresponding mutation type.  We then sum up the expected rates (i.e., all U) of all 
truncating mutation possibilities and all synonymous mutation possibilities, and the 
expected T/S site ratio is the former divided by the latter.  The dT/dS ratio is the 
observed T/S mutation ratio divided by the expected T/S site ratio.  Multiple testing 
was controlled using the method of Storey 55.  Table S8 contains the data. 
 
Software or URLs.  Bowtie2 56 for short reads mapping; Picard 
(http://picard.sourceforge.net) for removing duplicated short reads; GATK 57 for 
SNVs and indels calling; Cluster 3.0 58 for clustering analysis; R-package affy 59 for 
microarray data processing; BinGO 60 and GSEA for Gene Ontology analysis; 
ENSEMBL http://asia.ensembl.org; UCSC hg19 http://genome.ucsc.edu; ENCODE 
http://genome.ucsc.edu/ENCODE/; Bodymap 2.0 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30611; GO 
http://www.geneontology.org/;TumorScape 
http://www.broadinstitute.org/tumorscape; OrthoMCL http://orthomcl.org/orthomcl/. 
 
Supplementary Information can be found with this article online. 
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Figure Legends 
Figure 1. The evolving intratumoral genetic heterogeneity reveals positive 
selection on a set of multicellularity-related genes.  a. The area of a circle is 
proportional to the cell frequency of the subclone, which is also shown next to the 
circle (mean±s.e.m.).  The unfilled circle represents the subclone that became a 
mutator after XT4.  The number of mutations observed in the mutator subclone and 
in remaining parts of the tumor is shown at the left.  b. Allele frequency of the three 
missense mutations on MLL3, RAD54B, and PMS1.  c. GO terms enriched with 
genes mutated in the mutator subclone.  Arrows stand for “is_a”, and FDR is false 
discovery rate.  The number of mutated genes in each GO term is shown inside each 
circle.  d. The rate of non-silent mutations (missense, nonsense, and splicing-altering 
substitutions as well as indels) for each of the 14 multicellularity-related genes with 
non-synonymous mutations in the mutator subclone, and for all human protein-coding 
genes in a total of 772 breast cancer samples in TCGA.  e. dN > dS, a signature of 
positive selection on the 14 genes in breast cancer clinical samples.  Error bar shows 
one standard error. 
 
Figure 2. Functional properties of the ~700 genes with putative DEC.  a. The 
percentage of reduced expressions for putative DEC (driver expression change) 
genes and PEC (passenger expression change) genes, respectively.  Error bar shows 
one standard error.  b. The putative DEC genes are enriched in 
multicellularity-related GO terms.  Arrows stand for “is_a”, and FDR is false 
discovery rate.  c. An evolving expression profile approaching that of embryonic 
stem cells. 
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Figure 3. The birth rate of cancer drivers is peaked on B3, the deepest 
branch of metazoans.  a. The phylogenetic relationship of human and the 13 
major clades.  Emergence of the four early metazoan clades Ctenophora, Porifera, 
Placozoa, and Cnidaria was extremely compressed in time ~600 million years ago.  
The number of born genes is shown in parenthesis behind each branch, and the 
number of used genomes is shown behind each clade.  b. The birth rate of cancer 
drivers and pseudo-cancer drivers (y-axis), randomly selected genes with 
evolutionary rates comparable to cancer drivers, on each of the 13 branches (x-axis).  
Red triangles are for cancer drivers, and box plots are for pseudo-cancer drivers, 
with horizontal lines showing the median rates and black dots showing the 10th or the 
12990th rates of a branch out of 13,000 simulations.   
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 Legends for Supplemental Tables 1-9 
Table S1 Copy number information during the tumor evolution. This table 
contains copy number information of 10356 genomic regions in the 12 samples 
identified by comparative genomic hybridization (CGH).  There are 13 regions that 
show one-way copy number change during the tumor progression, and encompass 
breast cancer drivers identified by TumorScape.  It also includes 24 cancer driver 
genes annotated in Cancer Gene Census that are affected by copy-number-neutral loss 
of heterozygosity. 
 
Table S2 DNA alterations revealed by exome sequencing.  This table contains 
all single nucleotide variants (or mutations) and small indels covered by at least 30 
mapped reads in each of the 12 samples.  It also contains information of the 473 sites 
that were mutated after XT1 and considered in subclone separation.  In addition, the 
single-cell sequencing results that were used to assess the subclone separation are also 
included (grey represents mutations that are not grouped). 
 
Table S3 Expressions measured by log2RPKM for all the human genes 
annotated in Ensembl.  It also contains information of DEC and PEC genes. 
 
Table S4 Raw data for computing dN and dS of the 14 multicellularity-related 
genes.   
 
Table S5 Cancer gene sets enriched with the ~700 putative DEC genes. 
 
Table S6 The log2RPKM of the 73 breast biased genes in MCF10A-HRAS, 
XT8, 16 normal tissues and two human embryonic stem cells (hESCs).   We 
obtained RNA-seq data of the 16 normal tissues from Bodymap 2.0, and data of the 
two hESCs from ENCODE. 
 
Table S7 Genes and genomes in the phylostratigraphy analysis. 
 
Table S8 Tumour suppressor genes revealed by the dT/dS ratio test.  For each 
cancer type, the dT/dS ratio and the corresponding p-value (binomial test) are 
computed for each of the genes with ≥10 single-base substitution mutations in their 
coding sequences.  Genes with dT/dS significantly larger than 1, under the cutoff of q 
< 0.1 after controlling for multiple testing, are shown. 
 
Table S9 Gene expressions (log2RPKM) of XT1 cells growing in media with 
and without supplements. 
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 Legends for Supplemental Figures 1-9 
Fig. S1 A schematic diagram of the xenograft experimental evolution.   
 
Fig. S2 The phylogenetic relationship of the tumors revealed by their expression 
distance.  The expression distance of two samples was measured using 1-R, where R 
is the Pearson correlation coefficient of two log2-expression profiles, and the FM 
method (PHYLIP 3.69) was used to build the distance-based tree. 
 
Fig. S3 Determination of allele information for four mutations shared between 
XT8 and the two metastases.  The mutant allele frequencies in XT8 are 15.4%, 
4.8%, 5.3%, and 9.1% for locus 1, 2, 3, and 4, respectively.  TA-cloning based 
Sanger sequencing indicated that the G->A mutation is 100% present at one allele of 
locus 1 in the two metastases, suggesting that the two metastases originated 
exclusively from an XT8 subclone carrying this mutation.  Meanwhile, each of the 
three mutations at loci 2-4 is not 100% present at a specific allele, suggesting multiple 
cell origin of the two metastases. 
 
Fig. S4 The distribution of missense, nonsense, and synonymous mutations on 
the coding sequence of each of the 14 multicellularity-related genes.  The relative 
positions of the mutations on the coding sequences are shown. 
 
Fig. S5 Comparison of protein length and protein evolutionary rate between 
cancer drivers and the rest human genes.  a. The encoded protein length is similar 
between cancer drivers and the rest genes (K-S test is used).  b. Cancer drivers 
evolve slower than the rest genes (K-S test is used).   
 
Fig. S6 Comparison of the dN/dS test and dT/dS test in predicting ten canonical 
TSGs.  Pooled mutations from 4506 tumor samples of 13 cancer types were 
analyzed. 
 
Fig. S7 The novel tumour suppressors are enriched exclusively in the same four 
multicellularity-related GO terms as in the Fig. 1c.  The number of novel tumour 
suppressors in each GO term is shown in parenthesis.  FDR stands for false 
discovery rate. 
 
Fig. S8 The genes differentially expressed in the four-stage cell model are highly 
enriched in multicellularity-related GO terms.  The number of differentially 
expressed genes in each GO term is shown in parenthesis.  FDR stands for false 
discovery rate. 
 
Fig. S9 The observation of more cancer drivers on B3 holds after randomly 
removing 10% of genes from each of the three early animal clades, Placozoa, 
Porifera, and Ctenophora.  For Ctenophora and Placozoa, 10% of genes were 
randomly dropped out from the Trichoplax adhaerens and Mnemiopsis leidyi genomes, 
  3
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respectively.  For Porifera, 10 % of genes were removed from both the Amphimedon 
queenslandica and the Oscarella carmela genomes. The simulations were repeated 
100 times for each clade. 
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Fig. S9 
 
